EASL 2010: HIV/HCV Coinfected Patients with Acute Hepatitis C Are Equally Likely to Achieve Sustained Response with Interferon plus Ribavirin
- Details
- Category: Acute Hepatitis C
- Published on Friday, 07 May 2010 12:56
- Written by Liz Highleyman
HIV positive people with acute hepatitis C treated with pegylated interferon plus ribavirin, and HIV negative people treated with pegylated interferon alone, had a similar likelihood of achieving rapid virological response (RVR) at week 4 and sustained virological response (SVR) after completing treatment, according to findings presented at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL 2010) last month in Vienna. RVR was the best predictor of SVR, but HIV/HCV coinfected patients had larger HCV viral load reductions between weeks 4 and 12, suggesting that ribavirin promotes "third phase" viral decline.
More Articles...
- Chronic Hepatitis C Complications are Increasing, Especially among People Older than 60 Years
- Antibiotic Rifaximin Maintains Remission of Hepatic Encephalopathy in People with Advanced Liver Disease
- CROI 2010: Moderate Liver Fibrosis Predicts Disease and Death in HIV/HCV Coinfected People, but Successful Treatment Appears Protective
- Liver Transplant Do Not Impair Immune Response in HIV/HCV Coinfected Patients
- Daily Coffee Consumption Is Linked to Less Severe Liver Fibrosis
Web Design and Development by